CClinicalTrials.gg
CompletedNCT07117747SPECIMENUpdated Aug 12, 2025

Non-invasive Sampling Method for Skin Test: Optimization of Sample Collection and Extraction

An interventional study of Healthy volunteers in Healthy, sponsored by Essity Hygiene and Health AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Essity Hygiene and Health AB · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Aug 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

When absorbent hygiene products-such as panty liners, sanitary pads, incontinence products, or wound care items-are used over extended periods, they can sometimes have negative effects on the skin. The aim of the current study is to investigate the best way to measure the amount of cytokines on the skin through a non-invasive method.

Cytokines are small proteins that act as signaling molecules in the immune system and regulate inflammation and the body's response to infections. Because inflammatory markers often appear in very low concentrations in skin surface samples, it is essential to optimize both collection and extraction methods to overcome this limitation.

The researchers want to evaluate different sampling and extraction techniques to measure the skin's inflammatory response. The effectiveness assessment involves determining how well these methods can detect and analyze inflammatory markers. This includes ensuring the sampling methods are non-invasive yet sensitive enough to detect subtle changes in skin inflammation. Furthermore, the extraction methods must efficiently isolate relevant biomarkers to provide reliable data on the skin's response to the products.

Read the detailed description

The aim of this project was to refine a non-invasive skin sampling technique, enhancing cytokine recovery by optimizing both the sample collection method (tape stripping or swabbing) and the cytokine extraction solvent (including buffer type, detergent, and detergent concentration). The analytes of interest were the following five cytokines: IL-1α, IL-1RA, IL-6, IL-8, and TNF-α, which are signaling molecules in the immune system and important inflammatory biomarkers. ELISA was used for quantitative analysis.

Tape stripping and swabbing are two non-invasive skin sampling methods. For tape stripping, sample collection and extraction have been performed using D-Squame tape and an extraction buffer reported in relevant publications. Expanding the list of detectable cytokines allows for more accurate evaluations of skin condition.

02

Conditions studied

  • Healthy

Keywords

  • Absorbing hygiene product
  • Skin sampling
  • Cytokines
03

In context

Lead sponsor

Essity Hygiene and Health AB is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Sex: men/women
  • Age: >18 years
  • Subjects with full legal competence
  • Subjects who have provided a signed informed consent and willing to come to the scheduled visit at the test site

Exclusion criteria

Exclusion Criteria:

  • Subjects that have participated in any skin test that could cause damage to the skin barrier during the last 2 weeks
  • Subjects that have participated in any skin test that could cause damage to the skin barrier during the last 2 weeks
  • Subjects with known sensitivity or allergy to adhesives and nylon
  • Have immunodeficiency, taking any anti-inflammatory medication or having any other condition that makes participation in the clinical investigation inappropriate, as judged by investigator
  • Subjects with hairy forearms
  • Subjects with active skin diseases on the forearms
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Healthy volunteers

    Single arm study

    Other: Healthy volunteers

Interventions

  • OtherHealthy volunteers

    All subject belong to the same arm and ther is no intervention

06

What researchers measure

Primary outcomes

  1. Cytokine detection

    the detection of cytokines obtained by the different extraction solvents and sampling methods. ELISA complemented with the Micro BCA Protein Assay were used to quantify the cytokine recovery (in pg/ug total soluble protein).

    Time frame: 1-2 months

07

Study locations

1 site
  • Essity Study Site
    Mölndal, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07117747
Lead sponsor
Essity Hygiene and Health AB
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Mar 1, 2025
Primary completion
Apr 29, 2025
Completion
Jul 22, 2025
Last update
Aug 12, 2025

Study contacts

Warangkana Lohcharoenkal, PhD
principal investigator · Essity Hygiene and Health AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion